New oral anticoagulant drugs in cardiovascular disease

Thrombosis and Haemostasis

Volumn 104, Issue 1, 2010, Pages 49-60

  Ahrens, Ingo ^a   Lip, Gregory Y H ^b   Peter, Karlheinz ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiovascular disease; Direct thrombin inhibitor; Novel oral anticoagulants; Vitamin k antagonist; Xa inhibitor

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANISINDIONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATI 5923; AVIDIN; AZD 0837; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOCHROME P450 2C9; DABIGATRAN ETEXILATE; DICOUMAROL; DU 176B; EDOXABAN; ENOXAPARIN; ERIBAXABAN; IDRAPARINUX; MCC 977; MENADIONE EPOXIDE; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PD 0348292; PHENPROCOUMON; RIVAROXABAN; SOFIGATRAN; TAK 442; TECARFARIN; THROMBIN; THROMBIN INHIBITOR; TTP 889; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; YM 150;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; ANTICONVULSANT THERAPY; BLEEDING; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG HALF LIFE; HEART ATRIUM FIBRILLATION; HUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BENZIMIDAZOLES; CARDIOVASCULAR DISEASES; FACTOR XA; HUMANS; MORPHOLINES; PROTHROMBIN; PYRIDINES; THIOPHENES; VITAMIN K;

EID: 77954369172     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-05-0327     Document Type: Review

References (65)

1. Last JA. The Missing Link: The Story of Karl Paul Link. Toxicol Sci 2002; 66: 4-6.
2. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry 1978; 17: 1371-1377.
3. Kristiansen C, Lassen JF, Dahler-Eriksen BS, et al. Evaluation of a simple dosage scheme for transition from phenprocoumon to warfarin in oral anticoagulation. Thromb Res 2000; 98: 157-163. (Pubitemid 30122304)
4. van Geest-Daalderop JH, Pequeriaux NC, van den Besselaar AM. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements. Thromb Haemost 2009; 102: 588-592.
5. Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 2008; 47: 565-594.
6. Perez-Andreu V, Roldan V, Anton AI, et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977-4979.
7. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
8. Agnelli G, Eriksson BI, Cohen AT, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res 2009; 123: 488-497.
9. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-295. (Pubitemid 351508116)
10. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 2008; 48: 1411-1419.
11. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-956. (Pubitemid 47393577)
12. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-2185. (Pubitemid 47617868)
13. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009; 24: 1-9.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
15. Diener H-C, Connolly S, Ezekowitz MD, et al. Dabigatran Compared to Warfarin in Patients with Atrial Fibrillation and Prior TIA or Stroke: Results of RE-LY American Stroke Association International Stroke Conference 2010 - Late Braking Science 2010; Abstract 195.
16. Healey JS, Eikelboom J, Wallentin L, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: An analysis from the RE-LY study. . J Am Coll Cardiol 2010; 55: 1078-1120.
17. Koti MJ, Parekh A, Connolly SJ, et al. Dabigatran versus warfarin in patients with atrial fibrillation - An analysis of patients undergoing cardioversion. J Am Coll Cardiol 2010; 55: 1078-1124.
18. Oldgren J, Alings M, Darius H, et al. Dabigatran versus warfarin in atrial fibrillation patients with low, moderate and high CHADS2 score: A RE-LY subgroup analysis. J Am Coll Cardiol 2010; 55: 0903-0904.
19. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; epub ahead of print.
20. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med 2009; 361: 2342-2352.
21. Oldgren J, Budaj A, Granger C, et al. Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM). Circulation 2009; 120: 2160-2161, Abstract 165.
22. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists. Eur Heart J 2009; 30: 2897-2907.
23. Olsson SB, Rasmussen LH, Tveit A, et al. Safety and tolerability of an immediate-release formulation of theoral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation. Thromb Haemost 2010; 103: 604-612.
24. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost 2005; 3: 514-521.
25. Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-880.
26. Kubitza D, Becka M, Zuehlsdorf M, et al. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 2006; 46: 549-558.
27. Kubitza D, Becka M, Roth A, et al. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008; 24: 2757-2765.
28. Haas S. Rivaroxaban - an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Eur J Haematol 2009; 82: 339-349.
29. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
30. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008; 372: 31-39.
31. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
32. Turpie AG, Bauer KA, Davidson B, et al. Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 35.
33. Gibson C, Mega J, Hammett C, et al. Randomized Comparison of Rivaroxaban, an Oral Direct Factor Xa Inhibitor, with Placebo in Patients with Acute Coronary Syndromes: The ATLAS ACS-TIMI 46 Trial. Circulation 2008; 118: 2311.
34. Buller HR. Once-Daily Oral Rivaroxaban Versus Placebo in the Long-Term Prevention of Recurrent Symptomatic Venous Thromboembolism. the Einstein-Extension Study. ASH Annual Meeting Abstracts 2009. Blood 2009; 114: LBA-Abstract 2.
35. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009; 37: 74-81.
36. Lassen MR, Gallus AS, Pineo GF, et al. Randomized Double-Blind Comparison of Apixaban with Enoxaparin for Thromboprophylaxis after Knee Replacement: The ADVANCE-1 Trial. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 31.
37. Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 2009; 361: 594-604.
38. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375: 807-815.
39. Lassen MR, Davidson BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-2375.
40. Committee AS, Investigators. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. Circulation 2009; 119: 2877-2885.
41. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost 2008; 6: 1542-1549.
42. Fuji T, Fujita S, Tachibana S, et al. Randomized, Double-Blind, Multi-Dose Efficacy, Safety and Biomarker Study of the Oral Factor Xa Inhibitor DU-176b Compared with Placebo for Prevention of Venous Thromboembolism in Patients after Total Knee Arthroplasty. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 34.
43. Weitz JJ, Connolly SJ, Patel I, et al. Randomized, parallel-group, multicenter, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010; in press.
44. Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-meth oxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett 2009; 19: 2179-2185.
45. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost 2009; 101: 68-76.
46. Kohrt JT, Bigge CF, Bryant JW, et al. The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4- methoxypyrrolidine-1,2-dicarb oxamide (PD 0348292), an orally efficacious factor Xa inhibitor. Chem Biol Drug Des 2007; 70: 100-112.
47. Cohen AT, Armstrong D, Gazdzik T, et al. An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 980.
48. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost 2007; 5: 746-753. (Pubitemid 46563573)
49. Iwatsuki Y, Shigenaga T, Moritani Y, et al. Biochemical and Pharmacological Profiles of YM150, an Oral Direct Factor Xa Inhibitor. ASH Annual Meeting Abstracts 2006. Blood 2006; 108: Abstract 911.
50. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007; 5: 1660-1665.
51. Eriksson BI, Turpie AGG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010; 8: 714-721.
52. Kawamura M, Konishi N, Katsuhiko H, et al. Effects of TAK-442, a Direct FXa Inhibitor, and Fondaparinux on Platelet-Associated Prothrombinase in the Balloon Injured Artery of Rats. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 4077.
53. Konishi N, Hiroe K, Imaeda Y, et al. Differential Effects of TAK-442, a Factor Xa Inhibitor, and Ximelagatran, a Thrombin Inhibitor, on Bleeding: Possible Role of Differences in Effects on Factor V-Mediated Feedback on Blood Coagulation Cascade. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 5460.
54. Weitz JJ, Cao C, Eriksson B, et al. Phase II Dose-Finding Study with TAK-442, An Oral Factor Xa Inhibitor, in Patients Undergoing Elective Knee Arthroplasty. ASH Annual Meeting Abstracts 2009. Blood 2009; 114: Abstract 170.
55. Ellis DJ, Usman MH, Milner PG, et al. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 2009; 120: 1029-1035.
56. Eriksson BI, Dahl OE, Lassen MR, et al. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 2008; 6: 457-463.
57. Chan MY, Cohen MG, Dyke CK, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008 ; 117: 2865-2874.
58. Cohen MG, Purdy DA, Rossi JS, et al. First clinical application of an actively reversible direct factor IXa inhibitor in elective percutaneous coronary intervention. Eur Heart J 2009; 30 (Suppl 1): P686.
59. Veyrat-Follet C, Vivier N, Trellu M, et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J Thromb Haemost 2009; 7: 559-565.
60. Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371: 315-321.
61. Trellu M, Perez Y, Ortiz J, et al. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. J Thromb Haemost 2007; 5 (Suppl 2): P-T-678.
62. Buller HR, Destors J-M, Gallus AS, et al. Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 32.
63. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008; 47: 203-216.
64. Lu G, DeGuzman FR, Lakhotia S, et al. Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors. ASH Annual Meeting Abstracts 2008. Blood 2008; 112: Abstract 983.
65. Melnikova I. The anticoagulants market. Nat Rev Drug Discov 2009; 8: 353-354.